

# Mario Eisenberger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10557858/publications.pdf>

Version: 2024-02-01

29  
papers

8,355  
citations

304602

22  
h-index

477173

29  
g-index

29  
all docs

29  
docs citations

29  
times ranked

6947  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHARTED E3805. <i>Prostate</i> , 2022, 82, 1176-1185.	1.2	2
2	Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. <i>European Urology</i> , 2021, 80, 243-253.	0.9	28
3	Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. <i>European Journal of Cancer</i> , 2020, 125, 142-152.	1.3	7
4	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 470-475.e1.	0.9	26
5	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. <i>European Urology</i> , 2019, 75, 44-60.	0.9	48
6	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. <i>Journal of Clinical Oncology</i> , 2018, 36, 376-382.	0.8	75
7	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHARTED Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1080-1087.	0.8	702
8	Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m <sup>2</sup> ) and the Currently Approved Dose (25 mg/m <sup>2</sup> ) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3198-3206.	0.8	218
9	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 737-746.	13.9	2,112
10	Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. <i>Canadian Urological Association Journal</i> , 2013, 7, 74.	0.3	32
11	Is there a role for chemotherapy in nonmetastatic prostate cancer?. <i>Current Opinion in Supportive and Palliative Care</i> , 2010, 4, 141-146.	0.5	1
12	Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized Study. <i>Clinical Cancer Research</i> , 2010, 16, 5269-5276.	3.2	44
13	Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 203-211.	3.2	186
14	The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. <i>European Journal of Cancer</i> , 2010, 46, 517-525.	1.3	118
15	Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens. <i>Journal of the National Cancer Institute</i> , 2008, 100, 681-682.	3.0	4
16	Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 242-245.	0.8	987
17	Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study. <i>Clinical Cancer Research</i> , 2008, 14, 2763-2767.	3.2	179
18	Phase I Trial of the Prostate-Specific Membrane Antigen-Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2147-2154.	0.8	135

#	ARTICLE	IF	CITATIONS
19	Prognostic Value of Preoperative Serum Cell-Free Circulating DNA in Men with Prostate Cancer Undergoing Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2007, 13, 5361-5367.	3.2	82
20	A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis. <i>Clinical Cancer Research</i> , 2007, 13, 6396-6403.	3.2	341
21	Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3965-3970.	0.8	257
22	Death in Patients With Recurrent Prostate Cancer After Radical Prostatectomy: Prostate-Specific Antigen Doubling Time Subgroups and Their Associated Contributions to All-Cause Mortality. <i>Journal of Clinical Oncology</i> , 2007, 25, 1765-1771.	0.8	177
23	Treatment of Prostate Cancer in the 21st Century—Future Directions. <i>European Urology Supplements</i> , 2006, 5, 824-829.	0.1	1
24	Time to Prostate Specific Antigen Recurrence After Radical Prostatectomy and Risk of Prostate Cancer Specific Mortality. <i>Journal of Urology</i> , 2006, 176, 1404-1408.	0.2	110
25	Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture?. <i>Nature Reviews Urology</i> , 2006, 3, 246-247.	1.4	1
26	Risk of Prostate Cancer—Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 433.	3.8	1,186
27	Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 537-556.	0.8	189
28	Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone. <i>Journal of Clinical Oncology</i> , 2000, 18, 1440-1450.	0.8	176
29	Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , 1999, 17, 3461-3467.	0.8	931